TNF-like weak inducer of apoptosis (TWEAK) activates proinflammatory signaling pathways and gene expression through the activation of TGF-β-activated kinase 1

Journal of Immunology

Volumn 182, Issue 4, 2009, Pages 2439-2448

  Kumar, Mukesh ^a   Makonchuk, Denys Y ^a   Li, Hong ^a   Mittal, Ashwani ^a   Kumar, Ashok ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; FN14 RECEPTOR; GELATINASE B; I KAPPA B ALPHA; I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; JANUS KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEIN KINASE B; PROTEIN TWEAK; RECEPTOR; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR AP 1; TRANSFORMING GROWTH FACTOR BETA ACTIVATED KINASE 1; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; MAP KINASE KINASE KINASE 7; MITOGEN ACTIVATED PROTEIN KINASE KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; TNFSF12 PROTEIN, MOUSE; TUMOR NECROSIS FACTOR;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; FIBROBLAST; GENE EXPRESSION; INFLAMMATION; MOUSE; MYOBLAST; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TRANSACTIVATION; ANIMAL; CELL CULTURE; GEL MOBILITY SHIFT ASSAY; IMMUNOLOGY; IMMUNOPRECIPITATION; METABOLISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CELLS, CULTURED; ELECTROPHORETIC MOBILITY SHIFT ASSAY; ENZYME ACTIVATION; FIBROBLASTS; GENE EXPRESSION; IMMUNOPRECIPITATION; INFLAMMATION; MAP KINASE KINASE KINASES; MICE; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MYOBLASTS; NF-KAPPA B; PROTO-ONCOGENE PROTEINS C-AKT; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTOR AP-1; TUMOR NECROSIS FACTORS;

EID: 61449148439     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0803357     Document Type: Article

References (64)

1. Aggarwal, B. B. 2003. Signaling pathways of the TNF superfamily: a double-edged sword. Nat. Rev. Immunol. 3: 745-756.
2. Locksley, R. M., N. Killeen, and M. J. Lenardo. 2001. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 104: 487-501.
3. Aggarwal, B. B. 2000. Tumour necrosis factors receptor associated signalling molecules and their role in activation of apoptosis, JNK and NF-κB. Ann. Rheum. Dis. 59(Suppl.) 1: i6 -i16.
4. Chicheportiche, Y., P. R. Bourdon, H. Xu, Y. M. Hsu, H. Scott, C. Hession, I. Garcia, and J. L. Browning. 1997. TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis. J. Biol. Chem. 272: 32401-32410.
5. Winkles, J. A. 2008. The TWEAK-Fn14 cytokine-receptor axis: discovery, biology and therapeutic targeting. Nat. Rev. Drug Discov. 7: 411-425.
6. Winkles, J. A., N. L. Tran, S. A. Brown, N. Stains, H. E. Cunliffe, and M. E. Berens. 2007. Role of TWEAK and Fn14 in tumor biology. Front. Biosci. 12: 2761-2771.
7. Wiley, S. R., L. Cassiano, T. Lofton, T. Davis-Smith, J. A. Winkles, V. Lindner, H. Liu, T. O. Daniel, C. A. Smith, and W. C. Fanslow. 2001. A novel TNF receptor family member binds TWEAK and is implicated in angiogenesis. Immunity 15: 837-846.
8. Maecker, H., E. Varfolomeev, F. Kischkel, D. Lawrence, H. LeBlanc, W. Lee, S. Hurst, D. Danilenko, J. Li, E. Filvaroff, et al. 2005. TWEAK attenuates the transition from innate to adaptive immunity. Cell 123: 931-944.
9. Wiley, S. R., and J. A. Winkles. 2003. TWEAK, a member of the TNF superfamily, is a multifunctional cytokine that binds the TweakR/Fn14 receptor. Cytokine Growth Factor Rev. 14: 241-249.
10. Perper, S. J., B. Browning, L. C. Burkly, S. Weng, C. Gao, K. Giza, L. Su, L. Tarilonte, T. Crowell, L. Rajman, et al. 2006. TWEAK is a novel arthritogenic mediator. J. Immunol. 177: 2610-2620.
11. Dogra, C., H. Changotra, S. Mohan, and A. Kumar. 2006. Tumor necrosis factor-like weak inducer of apoptosis inhibits skeletal myogenesis through sustained activation of nuclear factor-κB and degradation of MyoD protein. J. Biol. Chem. 281: 10327-10336.
12. Dogra, C., H. Changotra, N. Wedhas, X. Qin, J. E. Wergedal, and A. Kumar. 2007. TNF-related weak inducer of apoptosis (TWEAK) is a potent skeletal muscle-wasting cytokine. FASEB J. 21: 1857-1869.
13. Kaplan, M. J., E. E. Lewis, E. A. Shelden, E. Somers, R. Pavlic, W. J. McCune, and B. C. Richardson. 2002. The apoptotic ligands TRAIL, TWEAK, and Fas ligand mediate monocyte death induced by autologous lupus T cells. J. Immunol. 169: 6020-6029.
14. Zhao, Z., L. C. Burkly, S. Campbell, N. Schwartz, A. Molano, A. Choudhury, R. A. Eisenberg, J. S. Michaelson, and C. Putterman. 2007. TWEAK/Fn14 interactions are instrumental in the pathogenesis of nephritis in the chronic graftversus-host model of systemic lupus erythematosus. J. Immunol. 179: 7949-7958.
15. Aktas, O., T. Prozorovski, and F. Zipp. 2006. Death ligands and autoimmune demyelination. Neuroscientist 12: 305-316.
16. Yepes, M., S. A. Brown, E. G. Moore, E. P. Smith, D. A. Lawrence, and J. A. Winkles. 2005. A soluble Fn14-Fc decoy receptor reduces infarct volume in a murine model of cerebral ischemia. Am. J. Pathol. 166: 511-520.
17. Iocca, H. A., S. R. Plant, Y. Wang, L. Runkel, B. P. O'Connor, E. T. Lundsmith, K. Hahm, H. W. van Deventer, L. C. Burkly, and J. P. Ting. 2008. TNF superfamily member TWEAK exacerbates inflammation and demyelination in the cuprizone-induced model. J. Neuroimmunol. 194: 97-106.
18. Potrovita, I., W. Zhang, L. Burkly, K. Hahm, J. Lincecum, M. Z. Wang, M. H. Maurer, M. Rossner, A. Schneider, and M. Schwaninger. 2004. Tumor necrosis factor-like weak inducer of apoptosis-induced neurodegeneration. J. Neurosci. 24: 8237-8244.
19. Tran, N. L., W. S. McDonough, P. J. Donohue, J. A. Winkles, T. J. Berens, K. R. Ross, D. B. Hoelzinger, C. Beaudry, S. W. Coons, and M. E. Berens. 2003. The human Fn14 receptor gene is up-regulated in migrating glioma cells in vitro and overexpressed in advanced glial tumors. Am. J. Pathol. 162: 1313-1321.
20. Tran, N. L., W. S. McDonough, B. A. Savitch, T. F. Sawyer, J. A. Winkles, and M. E. Berens. 2005. The tumor necrosis factor-like weak inducer of apoptosis (TWEAK)-fibroblast growth factor-inducible 14 (Fn14) signaling system regulates glioma cell survival via NFκB pathway activation and BCL-XL/BCL-W expression. J. Biol. Chem. 280: 3483-3492.
21. Hayden, M. S., and S. Ghosh. 2004. Signaling to NF-κB. Genes Dev. 18: 2195-2224.
22. Saitoh, T., M. Nakayama, H. Nakano, H. Yagita, N. Yamamoto, and S. Yamaoka. 2003. TWEAK induces NF-κB2 p100 processing and long lasting NF-κB activation. J. Biol. Chem. 278: 36005-36012.
23. Dogra, C., S. L. Hall, N. Wedhas, T. A. Linkhart, and A. Kumar. 2007. Fibroblast growth factor inducible 14 (Fn14) is required for the expression of myogenic regulatory factors and differentiation of myoblasts into myotubes: evidence for TWEAK-independent functions of Fn14 during myogenesis. J. Biol. Chem. 282: 15000-15010.
24. Polek, T. C., M. Talpaz, B. G. Darnay, and T. Spivak-Kroizman. 2003. TWEAK mediates signal transduction and differentiation of RAW264.7 cells in the absence of Fn14/TweakR: evidence for a second TWEAK receptor. J. Biol. Chem. 278: 32317-32323.
25. Brown, S. A., C. M. Richards, H. N. Hanscom, S. L. Feng, and J. A. Winkles. 2003. The Fn14 cytoplasmic tail binds tumour-necrosis-factor-receptor- associated factors 1, 2, 3 and 5 and mediates nuclear factor-κB activation. Biochem. J. 371: 395-403.
26. Han, S., K. Yoon, K. Lee, K. Kim, H. Jang, N. K. Lee, K. Hwang, and S. Young Lee. 2003. TNF-related weak inducer of apoptosis receptor, a TNF receptor superfamily member, activates NF-κB through TNF receptor-associated factors. Biochem. Biophys. Res. Commun. 305: 789-796.
27. Vince, J. E., D. Chau, B. Callus, W. W. Wong, C. J. Hawkins, P. Schneider, M. McKinlay, C. A. Benetatos, S. M. Condon, S. K. Chunduru, et al. 2008. TWEAK-FN14 signaling induces lysosomal degradation of a cIAP1-TRAF2 complex to sensitize tumor cells to TNFα. J. Cell Biol. 182: 171-184.
28. Yamaguchi, K., K. Shirakabe, H. Shibuya, K. Irie, I. Oishi, N. Ueno, T. Taniguchi, E. Nishida, and K. Matsumoto. 1995. Identification of a member of the MAPKKK family as a potential mediator of TGF-β signal transduction. Science 270: 2008-2011.
29. Adhikari, A., M. Xu, and Z. J. Chen. 2007. Ubiquitin-mediated activation of TAK1 and IKK. Oncogene 26: 3214-3226.
30. Shim, J. H., C. Xiao, A. E. Paschal, S. T. Bailey, P. Rao, M. S. Hayden, K. Y. Lee, C. Bussey, M. Steckel, N. Tanaka, et al. 2005. TAK1, but not TAB1 or TAB2, plays an essential role in multiple signaling pathways in vivo. Genes Dev. 19: 2668-2681.
31. Wald, D., M. Commane, G. R. Stark, and X. Li. 2001. IRAK and TAK1 are required for IL-18-mediated signaling. Eur. J. Immunol. 31: 3747-3754.
32. Huangfu, W. C., E. Omori, S. Akira, K. Matsumoto, and J. Ninomiya-Tsuji. 2006. Osmotic stress activates the TAK1-JNK pathway while blocking TAK1-mediated NF-κB activation: TAO2 regulates TAK1 pathways. J. Biol. Chem. 281: 28802-28810.
33. Mizukami, J., G. Takaesu, H. Akatsuka, H. Sakurai, J. Ninomiya-Tsuji, K. Matsumoto, and N. Sakurai. 2002. Receptor activator of NF-κB ligand (RANKL) activates TAK1 mitogen-activated protein kinase kinase kinase through a signaling complex containing RANK, TAB2, and TRAF6. Mol. Cell. Biol. 22: 992-1000.
34. Madhavan, S., M. Anghelina, D. Sjostrom, A. Dossumbekova, D. C. Guttridge, and S. Agarwal. 2007. Biomechanical signals suppress TAK1 activation to inhibit NF-κB transcriptional activation in fibrochondrocytes. J. Immunol. 179: 6246-6254.
35. Ninomiya-Tsuji, J., K. Kishimoto, A. Hiyama, J. Inoue, Z. Cao, and K. Matsumoto. 1999. The kinase TAK1 can activate the NIK-I κB as well as the MAP kinase cascade in the IL-1 signalling pathway. Nature 398: 252-256.
36. Takaesu, G., S. Kishida, A. Hiyama, K. Yamaguchi, H. Shibuya, K. Irie, J. Ninomiya-Tsuji, and K. Matsumoto. 2000. TAB2, a novel adaptor protein, mediates activation of TAK1 MAPKKK by linking TAK1 to TRAF6 in the IL-1 signal transduction pathway. Mol. Cell 5: 649-658.
37. Wang, C., L. Deng, M. Hong, G. R. Akkaraju, J. Inoue, and Z. J. Chen. 2001. TAK1 is a ubiquitin-dependent kinase of MKK and IKK. Nature 412: 346-351.
38. Hanafusa, H., J. Ninomiya-Tsuji, N. Masuyama, M. Nishita, J. Fujisawa, H. Shibuya, K. Matsumoto, and E. Nishida. 1999. Involvement of the p38 mitogen-activated protein kinase pathway in transforming growth factor-β-induced gene expression. J. Biol. Chem. 274: 27161-27167.
39. Moriguchi, T., N. Kuroyanagi, K. Yamaguchi, Y. Gotoh, K. Irie, T. Kano, K. Shirakabe, Y. Muro, H. Shibuya, K. Matsumoto, et al. 1996. A novel kinase cascade mediated by mitogen-activated protein kinase kinase 6 and MKK3. J. Biol. Chem. 271: 13675-13679.
40. Shirakabe, K., K. Yamaguchi, H. Shibuya, K. Irie, S. Matsuda, T. Moriguchi, Y. Gotoh, K. Matsumoto, and E. Nishida. 1997. TAK1 mediates the ceramide signaling to stress-activated protein kinase/c-Jun N-terminal kinase. J. Biol. Chem. 272: 8141-8144.
41. Silverman, N., R. Zhou, R. L. Erlich, M. Hunter, E. Bernstein, D. Schneider, and T. Maniatis. 2003. Immune activation of NF-κB and JNK requires Drosophila TAK1. J. Biol. Chem. 278: 48928-48934.
42. Srivastava, A. K., X. Qin, N. Wedhas, M. Arnush, T. A. Linkhart, R. B. Chadwick, and A. Kumar. 2007. Tumor necrosis factor-α augments matrix metalloproteinase-9 production in skeletal muscle cells through the activation of transforming growth factor-β-activated kinase 1 (TAK1)-dependent signaling pathway. J. Biol. Chem. 282: 35113-35124.
43. Kumar, A., S. K. Manna, S. Dhawan, and B. B. Aggarwal. 1998. HIV-Tat protein activates c-Jun N-terminal kinase and activator protein-1. J. Immunol. 161: 776-781.
44. Kumar, A., and A. M. Boriek. 2003. Mechanical stress activates the nuclear factor-κB pathway in skeletal muscle fibers: a possible role in Duchenne muscular dystrophy. FASEB J. 17: 386-396.
45. Wedhas, N., H. J. Klamut, C. Dogra, A. K. Srivastava, S. Mohan, and A. Kumar. 2005. Inhibition of mechanosensitive cation channels inhibits myogenic differentiation by suppressing the expression of myogenic regulatory factors and caspase-3 activity. FASEB J. 19: 1986-1997.
46. Kumar, A., Y. Takada, A. M. Boriek, and B. B. Aggarwal. 2004. Nuclear factor-κB: its role in health and disease. J. Mol. Med. 82: 434-448.
47. Hosokawa, Y., I. Hosokawa, K. Ozaki, H. Nakae, and T. Matsuo. 2006. Proinflammatory effects of tumour necrosis factor-like weak inducer of apoptosis (TWEAK) on human gingival fibroblasts. Clin. Exp. Immunol. 146: 540-549.
48. Kim, S. H., Y. J. Kang, W. J. Kim, D. K. Woo, Y. Lee, D. I. Kim, Y. B. Park, B. S. Kwon, J. E. Park, and W. H. Lee. 2004. TWEAK can induce pro-inflammatory cytokines and matrix metalloproteinase-9 in macrophages. Circ. J. 68: 396-399.
49. Ozes, O. N., L. D. Mayo, J. A. Gustin, S. R. Pfeffer, L. M. Pfeffer, and D. B. Donner. 1999. NF-κB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature 401: 82-85.
50. Romashkova, J. A., and S. S. Makarov. 1999. NF-κB is a target of AKT in anti-apoptotic PDGF signalling. Nature 401: 86-90.
51. Dogra, C., H. Changotra, J. E. Wergedal, and A. Kumar. 2006. Regulation of phosphatidylinositol 3-kinase (PI3K)/Akt and nuclear factor-κB signaling pathways in dystrophin-deficient skeletal muscle in response to mechanical stretch. J. Cell. Physiol. 208: 575-585.
52. Liu, H. H., M. Xie, M. D. Schneider, and Z. J. Chen. 2006. Essential role of TAK1 in thymocyte development and activation. Proc. Natl. Acad. Sci. USA 103: 11677-11682.
53. Sato, S., H. Sanjo, K. Takeda, J. Ninomiya-Tsuji, M. Yamamoto, T. Kawai, K. Matsumoto, O. Takeuchi, and S. Akira. 2005. Essential function for the kinase TAK1 in innate and adaptive immune responses. Nat. Immunol. 6: 1087-1095.
54. Tang, M., X. Wei, Y. Guo, P. Breslin, S. Zhang, W. Wei, Z. Xia, M. Diaz, S. Akira, and J. Zhang. 2008. TAK1 is required for the survival of hematopoietic cells and hepatocytes in mice. J. Exp. Med. 205: 1611-1619.
55. Sayama, K., Y. Hanakawa, H. Nagai, Y. Shirakata, X. Dai, S. Hirakawa, S. Tokumaru, M. Tohyama, L. Yang, S. Sato, et al. 2006. Transforming growth factor-β-activated kinase 1 is essential for differentiation and the prevention of apoptosis in epidermis. J. Biol. Chem. 281: 22013-22020.
56. Omori, E., K. Matsumoto, H. Sanjo, S. Sato, S. Akira, R. C. Smart, and J. Ninomiya-Tsuji. 2006. TAK1 is a master regulator of epidermal homeostasis involving skin inflammation and apoptosis. J. Biol. Chem. 281: 19610-19617.
57. Ninomiya-Tsuji, J., T. Kajino, K. Ono, T. Ohtomo, M. Matsumoto, M. Shiina, M. Mihara, M. Tsuchiya, and K. Matsumoto. 2003. A resorcylic acid lactone, 5Z-7-oxozeaenol, prevents inflammation by inhibiting the catalytic activity of TAK1 MAPK kinase kinase. J. Biol. Chem. 278: 18485-18490.
58. Malinin, N. L., M. P. Boldin, A. V. Kovalenko, and D. Wallach. 1997. MAP3K-related kinase involved in NF-κB induction by TNF, CD95 and IL-1. Nature 385: 540-544.
59. Woronicz, J. D., X. Gao, Z. Cao, M. Rothe, and D. V. Goeddel. 1997. IκB kinase-β: NF-κB activation and complex formation with IκB kinase-α and NIK. Science 278: 866-869.
60. Amaravadi, R., and C. B. Thompson. 2005. The survival kinases Akt and Pim as potential pharmacological targets. J. Clin. Invest. 115: 2618-2624.
61. Hennessy, B. T., D. L. Smith, P. T. Ram, Y. Lu, and G. B. Mills. 2005. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat. Rev. Drug Discov. 4: 988-1004.
62. Merlot, S., and R. A. Firtel. 2003. Leading the way: Directional sensing through phosphatidylinositol 3-kinase and other signaling pathways. J. Cell Sci. 116: 3471-3478.
63. Feng, F., L. Wang, N. Albanese, A. Holmes, and P. Xia. 2008. Tumor necrosis factor-like weak inducer of apoptosis attenuates the action of insulin in hepatocytes. Endocrinology 149: 1505-1513.
64. Li, H., A. Mittal, P. K. Paul, M. Kumar, D. S. Srivastava, S. C. Tyagi, and A. Kumar. 2008. Tumor necrosis factor-related weak inducer of apoptosis augments matrix metalloproteinase-9 production (MMP-9) in skeletal muscle through the activation of nuclear factor-κ B-inducing kinase and p38 mitogen-activated protein kinase; a potential role of MMP-9 in myopathy. J. Biol. Chem. Epub ahead of print.